about
Biomarkers of drug-induced vascular injury.Social housing of non-rodents during cardiovascular recordings in safety pharmacology and toxicology studiesA multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions.Provision of food and water in rodent whole body plethysmography safety pharmacology respiratory studies - Impact on animal welfare and data quality.Opportunities to Apply the 3Rs in Safety Assessment Programs.The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.Incorporation of capillary microsampling into whole body plethysmography and modified Irwin safety pharmacology studies in rats.Further investigations into the mechanism of the antihypertensive activity of the angiotensin AT1 receptor antagonist, GR138950.Role of K+ channels in A2A adenosine receptor-mediated dilation of the pressurized renal arcuate artery.Non-invasive telemetric electrocardiogram assessment in conscious beagle dogs.An Analysis of the Relationship Between Preclinical and Clinical QT Interval-Related Data.Refinement of the charcoal meal study by reduction of the fasting period.The effects of pharmacological modulation of KATP on the guinea-pig isolated diaphragm.Safety pharmacology--a progressive approachThe use of human tissue in safety assessmentOpportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluationPredicting the safety of medicines in pregnancy: A workshop reportReflections on the progress towards non-animal methods for acute toxicity testing of chemicalsSocial-housing and use of double-decker cages in rat telemetry studiesThe functional observational battery and modified Irwin test as global neurobehavioral assessments in the rat: Pharmacological validation data and a comparison of methodsIntegration of Consortia Recommendations for Justification of Animal Use Within Current and Future Drug Development ParadigmsNeurofunctional test batteries in safety pharmacology - Current and emerging considerations for the drug development process
P50
Q36176683-9D719DFD-78FD-4D2E-A38A-CA84ABC30987Q37324728-C833136A-BF05-4F22-91E0-8D56ACA4FE5DQ38105818-37BCD0B1-1DA5-4EAC-8F0C-7DE10D78580EQ38638830-B4C02FC3-26B1-4950-966C-025E8AE4AA70Q38774773-60B87191-FFBD-4381-B6E1-9CA1E770DA2EQ38925714-A2FC1AAF-9880-4472-A35B-380C12BAE72BQ40796930-EB8CCF33-B344-4C9B-AC7D-07C813D97685Q42703960-DCBEA9A4-BA8A-4223-B13B-1FA8ACE90DFFQ42974492-38747EF1-B29A-4ED3-A5CA-9C04DA1089C3Q45962823-0B3FF46F-4FAA-4060-9AEE-F107A23B447DQ46307567-35E2EC70-F256-4CD1-BC65-E307E32FAECFQ51354543-E840A677-151E-430F-A2B0-8282760E7F9CQ53988626-CF80FDC9-2E4F-4347-8C08-D6B748F351A8Q74582376-B0574088-6886-4DBE-80DA-DC6F872F9934Q88648084-5A39ABB1-740D-49CF-A4F1-D2151E93A961Q89999172-707B3CC4-1209-4B41-B508-430E82F06540Q89999349-77D93AAE-52AC-4521-BB3C-EBECEC2ACC08Q90714681-C3AA2213-9D0A-4000-8191-2F6978EA2135Q91704575-C6DFEF34-8117-4538-8EF0-AF082CC78002Q92406397-FFE94BC3-66E2-43F9-8EBE-286FF5CABF14Q92910215-230A7E9C-A394-47A8-A048-AB8BB0D7C1EEQ93014949-B37F34B8-39FF-421B-8E7A-9094F53AF22E
P50
description
researcher ORCID ID = 0000-0002-8700-7226
@en
name
Helen M Prior
@ast
Helen M Prior
@en
Helen M Prior
@es
Helen M Prior
@nl
type
label
Helen M Prior
@ast
Helen M Prior
@en
Helen M Prior
@es
Helen M Prior
@nl
prefLabel
Helen M Prior
@ast
Helen M Prior
@en
Helen M Prior
@es
Helen M Prior
@nl
P1153
7003984123
P31
P496
0000-0002-8700-7226